The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
Table 2
The clinicopathological features of HER2-low and HER2-negative subtypes in considering the HR expression status.
Clinicopathological characteristics
Hormone receptors negative
Hormone receptors positive
HER2 low (%)
HER2 negative (%)
HER2 low (%)
HER2 negative (%)
Age
0.3
0.5
<50yo
46.1
47.5
47.1
48.2
>50yo
53.9
52.5
52.9
51.8
SBR grade
<0.001
<0.001
I
41.2
22.5
28.1
1.0
II
35.9
53.5
49.7
35.3
III
19.3
20.8
20.5
59.7
NA
3.6
3.1
1.6
4.0
Tumor size
<0.001
<0.001
T0
0.0
0.4
0.0
1.0
T1
18.6
23.4
13.0
14.9
T2
30.9
40.7
24.9
46.8
T3
7.4
6.9
10.3
10.9
T4
1.3
6.7
1.6
10.0
TX
41.7
21.9
50.3
16.4
Lymph node
<0.001
0.005
N+
39.9
51.4
66.5
50.2
N0
38.2
40.4
28.6
42.8
NX
21.9
8.2
4.9
7.0
Tumor stage
0.001
<0.001
I
9.6
11.6
4.9
7.5
II
19.2
31.0
13.0
39.8
III
19.6
28.8
22.7
26.9
IV
1.1
2.8
1.1
4.0
NA
50.6
25.7
58.4
21.9
ER
—
—
Negative
—
—
100.0
100.0
Positive
100.0
100.0
—
—
PR
0.005
—
Negative
3.4
6.7
100.0
100.0
Positive
96.6
93.1
—
—
NA
0.0
0.3
—
—
Ki67
0.004
<0.001
<20%
39.2
45.6
5.4
10.4
>20%
49.5
41.1
90.8
62.7
NA
11.2
13.4
3.8
26.9
The values in bold presented in Table 2 indicate that the p value is less than 0.05.